本帖最后由 老马 于 2012-1-13 21:20 编辑
& w# ]7 o7 v) O3 E/ c, K" y* `6 l# z s" @) v+ Q f* p% ]2 Y# A
爱必妥和阿瓦斯丁的比较
# S* Z" l: T* y: Y t' c
- I8 M7 M# x2 p1 Y/ \6 h9 | V0 Khttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/: ~) G, G- @4 l
' \6 ]. k' ^: K, D9 A
( i7 |: R, ~! v6 w% s8 x
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
& ?2 T) H3 L4 c==================================================
, `) k8 X' @; n# p: b1 T& POverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) S: |' { A: M: A3 T4 A
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.* _; P2 I3 ^; J: [3 Q
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (～62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported., q( b- T! \8 z& Z6 b- G) V# H
|
显身卡
